Followers | 840 |
Posts | 121709 |
Boards Moderated | 10 |
Alias Born | 09/05/2002 |

Monday, April 17, 2023 12:37:16 PM
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention • Business Wire • 06/24/2025 10:45:00 AM
- Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH) • Business Wire • 06/23/2025 10:45:00 AM
- IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer • Business Wire • 06/18/2025 11:00:00 AM
- FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent • Business Wire • 06/13/2025 10:45:00 AM
- Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs • Business Wire • 06/12/2025 08:45:00 PM
- Merck Launches Final-Stage Trial of Dengue Vaccine for Children • IH Market News • 06/12/2025 01:51:02 PM
- Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate • Business Wire • 06/12/2025 10:45:00 AM
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season • Business Wire • 06/09/2025 07:11:00 PM
- Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia • Business Wire • 06/09/2025 10:45:00 AM
- Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference • Business Wire • 06/04/2025 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:45:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:25:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:22:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:21:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:18:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 05:05:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:58:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:55:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:53:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:51:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2025 04:49:42 PM
- KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC) • Business Wire • 05/31/2025 12:00:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/30/2025 01:56:39 PM
- Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations • Business Wire • 05/30/2025 12:05:00 PM
- Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial • Business Wire • 05/30/2025 12:00:00 PM
FEATURED MedWellAi, Inc (formerly Integrated Ventures) Completes Corporate Rebranding And Transformation Into Ai-Driven Healthcare and Wellness • Jun 24, 2025 8:45 AM
FEATURED Envirotech (EVTV) Announces Vision for Multi-modal Electric Mobility Ecosystem • Jun 24, 2025 8:42 AM
Avant Technologies Creating New Company for Expansion of Diabetes Program • AVAI • Jun 24, 2025 8:00 AM
From Exploration to Execution: New Gold Player Emerges in One of Canada's Premier Mining Districts • ABX • Jun 23, 2025 8:45 AM
Authentic Holdings Inc. Partnership with Swerve TV Debuts with Highly Successful 'Ring of Combat' Live Broadcast • AHRO • Jun 18, 2025 12:45 PM
ePIC Blockchain Signs LOI with A.R.T. Digital to Redefine Bitcoin Miner Design with Breakthrough Air-Cooling Technology • CGAC • Jun 18, 2025 12:41 PM